Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at the International Conference on Malignant Lymphoma

By: via Benzinga
Seattle Genetics, Inc. (NASDAQ: SGEN) today announced several ADCETRIS (brentuximab vedotin) data presentations at the 13th ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.